New insights in myeloma-induced osteolysis

被引:53
作者
Barillé-Nion, S [1 ]
Bataille, R [1 ]
机构
[1] INSERM, U463, F-44093 Nantes 1, France
关键词
multiple myeloma; osteolysis; RANKL/OPG; MIP-1; osteoprotegerin;
D O I
10.1080/1042819031000082966
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multiple myeloma (MM) is a plasma cell malignancy localized in the bone marrow (BM) and characterized by a high capacity for bone destruction. Almost all patients with MM have early osteolytic lesions, which result mainly from increased bone resorption related to stimulation of osteoclast recruitment and activity in the immediate vicinity of myeloma cells. The recent discovery of Osteoprotegerin (OPG) and the subsequent identification of its ligand RANKL have provided new insights in the regulation of osteoclastogenesis. The ratio OPG/RANKL is critical for the regulation of bone remodeling maintaining the balance between osteoblastic and osteoclastic activity. This review summarizes the new concept that myeloma cells induce in bone environment an imbalance in the OPG/RANKL system responsible for osteolysis observed in patients. Indeed, myeloma cells increase in bone environment the expression of the potent osteoclastogenic factor RANKL and decrease the osteoprotective factor OPG production. Biological mechanisms involved in these processes are discussed. Furthermore, the chemokines MIP-1alpha. and MIP-1beta belonging to the RANTES family are potent osteoclastogenic factors produced by myeloma cells and participate in myeloma-associated bone disease. These data open new avenues for the treatment of bone disease in MM and highlight the promising therapeutical interest of RANKL inhibitors (OPG and RANK-Fc) and MIP-1 inhibitors in the management of myeloma-associated osteolysis, besides bisphosphonates.
引用
收藏
页码:1463 / 1467
页数:5
相关论文
共 29 条
[1]   Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma [J].
Abe, M ;
Hiura, K ;
Wilde, J ;
Moriyama, K ;
Hashimoto, T ;
Ozaki, S ;
Wakatsuki, S ;
Kosaka, M ;
Kido, S ;
Inoue, D ;
Matsumoto, T .
BLOOD, 2002, 100 (06) :2195-2202
[2]   MECHANISMS OF BONE DESTRUCTION IN MULTIPLE-MYELOMA - THE IMPORTANCE OF AN UNBALANCED PROCESS IN DETERMINING THE SEVERITY OF LYTIC BONE-DISEASE [J].
BATAILLE, R ;
CHAPPARD, D ;
MARCELLI, C ;
DESSAUW, P ;
SANY, J ;
BALDET, P ;
ALEXANDRE, C .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (12) :1909-1914
[3]   Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: A prospective study of 87 bone biopsies [J].
Bataille, R ;
Chappard, D ;
Basle, MF .
BLOOD, 1996, 87 (11) :4762-4769
[4]   Multiple myeloma [J].
Bataille, R ;
Harousseau, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (23) :1657-1664
[5]   The effect of a single dose of osteoprotegerin in postmenopausal women [J].
Bekker, PJ ;
Holloway, D ;
Nakanishi, A ;
Arrighi, M ;
Leese, PT ;
Dunstan, CR .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (02) :348-360
[6]  
CAPPARELLI C, 2000, CANCER RES, V60, P7873
[7]   Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease [J].
Choi, SJ ;
Oba, Y ;
Gazitt, Y ;
Alsina, M ;
Cruz, J ;
Anderson, J ;
Roodman, GD .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (12) :1833-1841
[8]   Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma [J].
Croucher, PI ;
Shipman, CM ;
Lippitt, J ;
Perry, M ;
Asosingh, K ;
Hijzen, A ;
Brabbs, AC ;
van Beek, EJR ;
Holen, I ;
Skerry, TM ;
Dunstan, CR ;
Russell, GR ;
Van Camp, B ;
Vanderkerken, K .
BLOOD, 2001, 98 (13) :3534-3540
[9]   Anti-myeloma activity of pamidronate in vivo [J].
Dhodapkar, MV ;
Singh, J ;
Mehta, J ;
Fassas, A ;
Desikan, KR ;
Perlman, M ;
Munshi, NC ;
Barlogie, B .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (02) :530-532
[10]   Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment [J].
Giuliani, N ;
Bataille, R ;
Mancini, C ;
Lazzaretti, M ;
Barillé, S .
BLOOD, 2001, 98 (13) :3527-3533